Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.
Category: #health  By Pankaj Singh  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet.

Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor Sprinkle™ (rosuvastatin) capsules, a drug designed specifically to treat patients with elevated lipid disorders.

According to sources, Ezallor Sprinkle is indicated as an adjunct to diet for treating adults with hypertriglyceridemia, primary dysbetalipoproteinemia (type III hyperlipoproteinemia), and other lipid-lowering treatments like LDL apheresis. It also acts as a monotherapy to lower LDL-C, total cholesterol, and ApoB in patients with homozygous familial hypercholesterolemia.

Speaking on the launch, Abhay Gandhi, CEO, North America, Sun Pharma, said that their firm, with Ezallor Sprinkle, will continue on its commitment to provide a portfolio of alternative formulation products that address the needs of patients facing difficulty in swallowing, which is particularly prevalent among residents in long-term care facilities who cannot swallow.

He said that these patients often encounter more medicinal errors and problems with medication administration compared to long-term care residents who don’t face such swallowing difficulties.

Commenting on the issue, Dr. Chris Chappel, Certified Medical Director, Chappel Group Research & Chappel Senior Care, said that the risk of medication errors increases when patients face difficulty in swallowing due to crushing of medicines that should not be crushed, or from residual medication left in crushing devices.

He said that Ezallor Sprinkle’s formulation will help in administering medication for patients with common elevated lipid disorders, especially in the elderly population.

For the record, Ezallor Sprinkle is developed as an extended-release-coated capsule that can be sprinkled over soft food, can be swallowed as whole, or administered through a nasogastric tube to facilitate long-term, once-daily administration.

It combines with Kapspargo Sprinkle™ extended-release tablets as the second drug in the Sun Pharma portfolio designed specifically for individuals in long-term care.

Reports cite that Ezallor Sprinkle is contraindicated in patients with known hypersensitivity to rosuvastatin, which may include pruritus, urticaria, rash, and angioedema. Moreover, in controlled clinical trials, the most common adverse reactions with rosuvastatin were abdominal pain, asthenia, headache, myalgia, and nausea.

Source Credit: https://www.businesswire.com/news/home/20190714005038/en/Sun-Pharma-Launches-Ezallor-Sprinkle-Rosuvastatin-U.S



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...